Latest News for: squibb
Edit
Arthralgia Market: Accelerating Growth and Pipeline Impact – DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB ...
GetNews 10 Feb 2026
Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others.
Edit
Bladder Cancer Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Bristol-Myers Squibb ...
GetNews 10 Feb 2026
The Key Bladder Cancer Companies in the market include - Bristol-Myers Squibb Company, GlaxoSmithKline PLC., Johnson & Johnson (Janssen Pharmaceutical), F ... Bristol-Myers Squibb ... BristolMyers Squibb.
Edit
The Galveston Daily News
09 Feb 2026
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
Edit
The Galveston Daily News
05 Feb 2026
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
Edit
Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth
Wall Street Journal 05 Feb 2026
Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs ... .
Edit
Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade
CNBC 05 Feb 2026
Chris Boerner, Bristol Myers Squibb CEO, joins 'Power Lunch' to discuss the company's quarterly earnings results, the drug pipeline and much more ... .
Edit
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025
The Call 05 Feb 2026
Biopharmaceutical company Bristol Myers Squibb (NYSE ... Is now the time to buy Bristol-Myers Squibb? Find out by accessing our full research report, it’s free. Bristol-Myers Squibb (BMY) Q4 CY2025 Highlights..
Edit
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 (Form 8-K) (Bristol-Myers Squibb Company)
Public Technologies 05 Feb 2026
) Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 ... (PRINCETON, N.J., February 5, 2026) - Bristol Myers Squibb (NYSE ... Bristol Myers Squibb is providing key 2026 non-GAAP line-item guidance as outlined below.
Edit
Q4 2025 Results Presentation (Bristol-Myers Squibb Company)
Public Technologies 05 Feb 2026
) Q4 2025 Results. February 5, 2026. Not for Product Promotional Use. Q4 2025 Results. Chris Boerner, PhD ... $7.4. $6.4 ... Bristol-Myers Squibb Company published this content on February 05, 2026, and is solely responsible for the information contained herein.
Edit
Q4 2025 Results Presentation (with Appendix) (Bristol-Myers Squibb Company)
Public Technologies 05 Feb 2026
) Q4 2025 Results. February 5, 2026. Not for Product Promotional Use. Q4 2025 Results. Chris Boerner, PhD ... $7.4. $6.4 ... Bristol-Myers Squibb Company published this content on February 05, 2026, and is solely responsible for the information contained herein.
Edit
Rutland Herald
04 Feb 2026
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
Edit
OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb
Nasdaq Globe Newswire 04 Feb 2026
... its strategic partnership with Bristol Myers Squibb (“BMS”) (NYSE.
Edit
Bristol-Myers Squibb Earnings: What To Look For From BMY
The Call 04 Feb 2026
Biopharmaceutical company Bristol Myers Squibb (NYSE ... Bristol-Myers Squibb beat analysts’ revenue expectations by 3.7% last quarter, reporting revenues of $12.22 billion, up 2.9% year on year.
Edit
The Eagle-Tribune
03 Feb 2026
Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in ...
- 1
- 2
- Next page »